Please login to the form below

Not currently logged in
Email:
Password:

Russian market for lung cancer drugs to hit $163m by 2015

Analysts predict three per cent sales growth for non-small cell lung cancer drugs

Sales of drugs for non-small cell lung cancer (NSCLC) are expected to see three per cent annual growth in Russia over the next four years and hit $163m by 2015.

Market growth will also be led by gradually rising use of higher-priced chemotherapies and the introduction of several premium-priced agents.

"As the incident non-small-cell lung cancer population grows in Russia, sales of most drug classes are expected to grow through 2015," said Decision Resources analyst Natalia Reoutova.

"The most dramatic growth will likely be seen in the kinase inhibitors drug class where three emerging agents - Boehringer Ingelheim's afitinib, Pfizer's dacomitinib and ArQule/Daiichi Sankyo/Kyowa Hakko Kirin's tivantinib - should make their debut in or before 2015."

Boehringer's afitinab is currently in phase III trials for NSCLC and breast cancer, and phase II trials for prostate and head and neck cancers, as well as glioma. The next generation tyrosine kinase inhibitor, targets the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2).

Pfizer's dacomitinib is also in phase III trials for NSCLC and the company signed up to use Qiagen's KRAS diagnostic test in August in a bid to help differentiate its drug from Roche's Tarceva (erlotinib), currently the top-selling NSCLC treatment.

Meanwhile, Daiichi Sankyo began enrolling patients in Europe into a large, multinational phase III trial of tivantinib, its investigational small molecule inhibitor of the c-MET receptor tyrosine kinase, in April this year.

Russia has a higher incidence of the disease than its fellow BRIC countries of Brazil, India and China, and analysts at Decision Resources say levels are comparable to those seen in the UK and US.

According to Decision Resources' 'Non-Small-Cell Lung Cancer in Russia' report, increasing smoking prevalence in men, in conjunction with an aging population will drive an increase in NSCLC incidence in the country.

Lung cancer is one of the most common cancers Europe and the leading cause of cancer-related death among men and women, and NSCLC is the most common form of the disease, accounting for approximately 85 per cent of all lung cancer cases.

15th December 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics